Author:
Vulsteke Christof,Chambers Setsuko K.,Pérez Maria Jesús Rubio,Chan John K.,Raaschou-Jensen Nicoline,Zhuo Ying,Lorusso Domenica,Herzog Thomas J.,de la Motte Rouge Thibault,Thomes Pepin Jessica A.,Braicu Elena Ioana,Chen Lee-may,Levy Tally,Barter James F.,Pilar Barretina-Ginesta M.,Joosens Eric,York Whitney,Malinowska Izabela A.,González-Martín Antonio,Monk Bradley J.
Reference17 articles.
1. Niraparib in patients with newly diagnosed advanced ovarian cancer;González-Martín;N Engl J Med,2019
2. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer;González-Martín;Eur J Cancer,2023
3. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial;Li;JAMA Oncol,2023
4. Zejula (niraparib). Package insert. GSK. April 2023.
5. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. National Institue for Health and Care Excellence. January 2021. Available from: https://www.nice.org.uk/guidance/ta673/documents/final-appraisal-determination-document. Accessed March 15, 2024.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献